Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer

Caio M. Rocha-Lima, Luis E. Raez

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Erlotinib (Tarceva) is a small-molecule, orally dosed, anticancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.

Original languageEnglish
Pages (from-to)554-564
Number of pages11
JournalP and T
Volume34
Issue number10
StatePublished - Oct 1 2009

Fingerprint

Pancreatic Neoplasms
Non-Small Cell Lung Carcinoma
Therapeutics
Combination Drug Therapy
Epidermal Growth Factor Receptor
Survival
Erlotinib Hydrochloride
Pharmaceutical Preparations
Population
Clinical Studies

Keywords

  • EGFR mutation
  • Erlotinib
  • Non-small-cell lung cancer
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. / Rocha-Lima, Caio M.; Raez, Luis E.

In: P and T, Vol. 34, No. 10, 01.10.2009, p. 554-564.

Research output: Contribution to journalArticle

Rocha-Lima, CM & Raez, LE 2009, 'Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer', P and T, vol. 34, no. 10, pp. 554-564.
Rocha-Lima, Caio M. ; Raez, Luis E. / Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. In: P and T. 2009 ; Vol. 34, No. 10. pp. 554-564.
@article{a767e04126c04266a18ecc9bb84236ae,
title = "Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer",
abstract = "Erlotinib (Tarceva) is a small-molecule, orally dosed, anticancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.",
keywords = "EGFR mutation, Erlotinib, Non-small-cell lung cancer, Pancreatic cancer",
author = "Rocha-Lima, {Caio M.} and Raez, {Luis E.}",
year = "2009",
month = "10",
day = "1",
language = "English",
volume = "34",
pages = "554--564",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "10",

}

TY - JOUR

T1 - Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer

AU - Rocha-Lima, Caio M.

AU - Raez, Luis E.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Erlotinib (Tarceva) is a small-molecule, orally dosed, anticancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.

AB - Erlotinib (Tarceva) is a small-molecule, orally dosed, anticancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.

KW - EGFR mutation

KW - Erlotinib

KW - Non-small-cell lung cancer

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=70450248381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450248381&partnerID=8YFLogxK

M3 - Article

C2 - 20140116

AN - SCOPUS:70450248381

VL - 34

SP - 554

EP - 564

JO - P and T

JF - P and T

SN - 1052-1372

IS - 10

ER -